{"protocolSection":{"identificationModule":{"nctId":"NCT05733416","orgStudyIdInfo":{"id":"20230006-01H"},"organization":{"fullName":"Ottawa Hospital Research Institute","class":"OTHER"},"briefTitle":"Intensive Cancer Screening After Cryptogenic Stroke","officialTitle":"Intensive Cancer Screening After Cryptogenic Stroke (INCOGNITO) Pilot Randomized Trial","acronym":"INCOGNITO"},"statusModule":{"statusVerifiedDate":"2023-10","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-09-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2026-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2023-01-28","studyFirstSubmitQcDate":"2023-02-08","studyFirstPostDateStruct":{"date":"2023-02-17","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-10-30","lastUpdatePostDateStruct":{"date":"2023-11-01","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Ottawa Hospital Research Institute","class":"OTHER"},"collaborators":[{"name":"Brain Canada","class":"OTHER"},{"name":"Heart and Stroke Foundation of Canada","class":"OTHER"},{"name":"Canadian Stroke Consortium (CSC)","class":"OTHER"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening strategy of FDG PET/CT in addition to usual care increases the number of occult cancers diagnosed after screening compared to usual care cancer screening alone in patients with cryptogenic stroke."},"conditionsModule":{"conditions":["Occult Cancer"],"keywords":["cryptogenic stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":45,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Intensive Cancer Screening","type":"EXPERIMENTAL","description":"Usual care plus PDG PET/CT","interventionNames":["Diagnostic Test: FDG PET/CT"]},{"label":"Usual Care","type":"OTHER","description":"Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care)","interventionNames":["Diagnostic Test: Usual Care"]}],"interventions":[{"type":"DIAGNOSTIC_TEST","name":"FDG PET/CT","description":"F-fluorodeoxyglucose positron emission/computed tomography","armGroupLabels":["Intensive Cancer Screening"]},{"type":"DIAGNOSTIC_TEST","name":"Usual Care","description":"Cancer screening according to sex, age and risk as per Canadian Task Force on Preventative Health Care","armGroupLabels":["Usual Care"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Participant Recruitment","description":"Number of participants recruited","timeFrame":"Over 12 months"}],"secondaryOutcomes":[{"measure":"Eligibility Rate","description":"proportion of screened patients who are eligible","timeFrame":"Over 12 months"},{"measure":"Consent Rate","description":"proportion of eligible patients who provide consent","timeFrame":"Over 12 months"},{"measure":"Retention Rate","description":"proportion of participants retained at follow-up","timeFrame":"Over 24 months"},{"measure":"Study Completion Rate","description":"proportion of participants who completed all study procedures","timeFrame":"Over 24 months"},{"measure":"Adherence Rate","description":"adherence to screening strategy","timeFrame":"Over 24 months"}],"otherOutcomes":[{"measure":"Screening time frame","description":"time from diagnosis to screening","timeFrame":"Over 24 months"},{"measure":"Reasons for participation","description":"Reasons for accepting/declining participation","timeFrame":"Over 24 months"},{"measure":"Usual care cancer screening strategies","description":"Usual care cancer screening strategies ordered by treating physicians","timeFrame":"Over 24 months"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* adults â‰¥18 years\n* presenting to the Ottawa Hospital Stroke Prevention Clinic or the Ottawa Hospital Neurovascular Unit with a first cryptogenic ischemic stroke after advanced evaluation as per American Heart Association guidelines and Saver approach (maximum 3 months after stroke)\n* patient or delegate willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* contraindications to FDG PET/CT (pregnancy or unable to lie still in bed for 20 minutes)\n* active cancer or previous cancer diagnosis (other than basal or squamous cell carcinoma of the skin)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"The Ottawa Hospital","status":"RECRUITING","city":"Ottawa","state":"Ontario","zip":"K1Y 4E9","country":"Canada","contacts":[{"name":"Michele Demetroff","role":"CONTACT","phone":"6137985555","email":"mdemetrof@ohri.ca"},{"name":"Dar Dowlatshahi, MD PhD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":45.41117,"lon":-75.69812}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Cryptogenic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M21376","name":"Fluorodeoxyglucose F18","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}